Amwell, a SaaS-based digital health platform for telehealth and hybrid care delivery, released fourth-quarter and full-year 2025 results on February 12, 2026. Top-line contraction stemmed mainly from the elimination of key Defense Health Agency (DHA) programs and attrition of older contracts, while the company narrowed losses through aggressive cost reductions and a strategic shift toward core payor and government clients.
Amwell’s results reflect ongoing pressures from government contract changes (particularly DHA programs), with significant top-line erosion. Expense discipline and a targeted path to cash flow breakeven in Q4 2026 help offset some of this, though reimbursement uncertainty, utilization trends and reliance on large contracts remain key risks for the company.
Performance in Telehealth Services:
Virtual care demand remained soft in 2025 amid payor reimbursement constraints, competition from in-person settings and broader healthcare spending pressures. Full-year revenue fell to $249.3 million while Q4 revenue dropped 22.1% year over year to $55.3 million. The primary factor was the DHA’s summer 2025 elimination of digital behavioral health and automated care programs under a cost-efficiency directive despite renewal of the underlying contract.
Subscription revenue (now 53% of total) fell 22% in Q4 reflecting the DHA impact and attrition of legacy agreements. Platform visits declined materially. Adjusted EBITDA loss narrowed to $10.3 million in Q4 (improved from prior periods) and full-year adjusted EBITDA loss was approximately $39.9 million. Q4 net loss was $25.2 million. Gross margin compressed 280 basis points to 51.2% due to mix changes and portfolio shifts. Amwell ended the year with approximately $182 million in cash and no debt.
Revenue and Profitability Trends:
The revenue decline stemmed primarily from DHA program cuts and non-renewal of older contracts. Company management acknowledged near-term margin pressure from these shifts, although operating expense reductions and a streamlined focus on higher-quality enterprise and payor relationships helped contain losses. Adjusted EBITDA improvement reflected execution on cost controls and deliberate divestiture of lower-margin areas.
2026 Outlook and Strategic Priorities:
Amwell issued 2026 guidance reflecting a more focused revenue base:
- Revenue: $195–$205 million.
- AMG visits: 1.32–1.37 million.
- Adjusted EBITDA loss: $24–$18 million.
- Q1 2026 revenue: $48–$53 million; adjusted EBITDA loss: $7–$5 million.
The outlook assumes continued cost discipline, enterprise renewals and government market expansion, with management maintaining a target for positive operating cash flow from operations in Q4 2026.
CEO Dr. Ido Schoenberg described 2025 as a year of significant transformation noting the company entered 2026 with clearer visibility toward cash flow breakeven. He emphasized same-store growth and payor relationships as foundational to stabilizing performance.
Future Considerations in Digital Health Services:
Amwell operates in a maturing telehealth market shaped by hybrid care adoption, payor policy uncertainty, clinician shortages and rising behavioral health/GLP-1 utilization costs. Heavy dependence on government contracts (including the upcoming DHA renewal in summer 2026) introduces risk of further changes or unfavorable terms.
The company has no debt and has been reducing its losses, which gives it some room to execute potential strategic partnerships. For anyone following consolidation in digital health, Amwell is a prime example of the post-pandemic adjustment: still platform-focused, yet held back by falling revenue reimbursement pressures and dependence on a few key contracts. Progress on 2026 targets will be critical in determining whether it influences broader digital health deal activity as a partner, buyer or seller.
